Compare
Lifevantage Corp vs Siga Technologies Inc vs Sinovac Biotech Ltd vs Nurix Therapeutics, Inc.
| Latest fiscal year | Lifevantage Corp LFVN | Siga Technologies Inc SIGA | Sinovac Biotech Ltd SVA | Nurix Therapeutics, Inc. NRIX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-11-30 |
| Revenue | $182.59M | $94.57M | $386.01M | $83.98M |
| Revenue growth (YoY) | -20.1% | -31.8% | +6.8% | +54.0% |
| Gross margin | 77.6% | 68.6% (computed) | 67.9% | n/a |
| Operating margin | 3.3% | 25.1% | -127.0% | -340.2% |
| Net margin | 2.8% | 24.6% | -51.5% | -314.9% |
| Net income | $5.07M | $23.28M | -$198.84M | -$264.46M |
| EPS (Diluted) | $0.40 | $0.32 | -$0.83 | -$3.05 |
| Operating cash flow | $10.24M | $43.47M | -$512.18M | -$249.47M |
| Free cash flow | $6.67M | n/a | -$561.10M | -$263.47M |
| Cash & equivalents | n/a | $154.97M | $488.25M | $246.96M |
| Total assets | $62.11M | $219.47M | $8.54B | $688.13M |
| Total liabilities | $28.52M | $20.65M | $2.15B | $149.39M |
| Shareholders' equity | $33.59M | $198.82M | $6.40B | $538.75M |
| Return on year-end equity | 15.1% | 11.7% | -3.1% | -49.1% |
| Shares outstanding | 12.52M | 71.61M | 71.86M | 101.81M |
Revenue, most recent five fiscal years
| Fiscal year | Lifevantage Corp | Siga Technologies Inc | Sinovac Biotech Ltd | Nurix Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $182.59M Ended 2026-06-30 | $94.57M Ended 2025-12-31 | $386.01M Ended 2025-12-31 | $83.98M Ended 2025-11-30 |
| 1 year earlier | $228.53M Ended 2025-06-30 | $138.72M Ended 2024-12-31 | $361.37M Ended 2024-12-31 | $54.55M Ended 2024-11-30 |
| 2 years earlier | $200.16M Ended 2024-06-30 | $139.92M Ended 2023-12-31 | $470.17M Ended 2023-12-31 | $76.99M Ended 2023-11-30 |
| 3 years earlier | $213.40M Ended 2023-06-30 | $110.78M Ended 2022-12-31 | $1.47B Ended 2022-12-31 | $38.63M Ended 2022-11-30 |
| 4 years earlier | $206.36M Ended 2022-06-30 | $133.67M Ended 2021-12-31 | $19.37B Ended 2021-12-31 | $29.75M Ended 2021-11-30 |